Skip to main content

PET/CT of Salivary Gland Tumors

  • Chapter
  • First Online:
Atlas of PET/CT in Oncology - Volume 1
  • 137 Accesses

Abstract

Salivary glands are exocrine glands that produce and secrete saliva. They include three paired major glands (parotid gland, submandibular gland, and sublingual gland) and minor salivary glands that widely exist in the entire respiratory and digestive tract. Many minor salivary gland tumors are located on the hard palate. The global annual incidence of salivary gland tumors is 0.4/100,000–13.5/100,000, and that of malignant tumors is 0.4/100,000–2.6/100,000, accounting for 0.7%–1.6% of all malignant tumors and 2.3%–10.4% of head and neck malignant tumors. Most of the salivary gland tumors are benign, but about 20% of parotid gland tumors are malignant; the incidence of submandibular gland and minor salivary gland malignant tumors is about 50% and 80%, respectively. Nearly 80% of salivary gland tumors occur in the parotid gland, most commonly in the superficial lobe, less than 1% in the sublingual gland, and 9%–23% in the minor salivary glands. The proportion of malignant tumors is different in different parts: 20%–30%, 45%–60%, and 70%–85% in the parotid gland, submandibular gland, and sublingual gland, respectively; 80%–90% of salivary gland tumors in the tongue, floor of the mouth, and retromolar area are malignant. Salivary gland tumors are slightly more common in women, with the peak age of onset ranging from 50 to 70 years, but the peak age of pleomorphic adenoma, mucoepidermoid carcinoma, and acinus cell carcinoma is 20–40 years. Among all salivary gland tumors, pleomorphic adenoma is the most common, accounting for about 50%, usually occurring in young adults aged 30–50 years without significant gender difference. The second most common is Warthin tumor (adenolymphoma), which is common in men over 50 years old; it is usually multiplex or bilateral, mostly located in the inferior superficial lobe of the parotid gland; almost all of Warthin tumors come from the parotid gland or peripheral lymph nodes. Others such as hemangioma, lymphangioma, and lipoma are rare. The most common malignant tumor is mucoepidermoid carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Further Reading

  • Hsieh C E, Ho K C, Hsieh C H, et al. Pretreatment primary tumor SUVmax on 18F-FDG PET/CT images predicts outcomes in patients with salivary gland carcinoma treated with definitive intensity-modulated radiation therapy. Clin Nucl Med 2017; 42(9):655-662.

    Article  PubMed  Google Scholar 

  • Jeong H S, Chung M K, Son Y I, et al. Role of 18F-FDG PET/CT in management of high-grade salivary gland malignancies. J Nucl Med, 2007; 48(8):1237-1244.

    Article  PubMed  Google Scholar 

  • Kim M J, Kim J S, Roh J L, et al. Utility of 18F-FDG PET/CT for detecting neck metastasis in patients with salivary gland carcinomas: preoperative planning for necessity and extent of neck dissection. Ann Surg Oncol 2013; 20(3):899-905.

    Article  PubMed  Google Scholar 

  • Nguyen B D, Roarke M C. Salivary duct carcinoma with perineural spread to facial canal 18F-FDG PET/CT detection. Clin Nucl Med 2008; 33(12):925-928.

    Article  PubMed  Google Scholar 

  • Park M J, Oh J S, Roh J L, et al. 18F-FDG PET/CT versus contrast-enhanced CT for staging and prognostic prediction in patients with salivary gland carcinomas. Clin Nucl Med, 2017; 42(3):e149-e156.

    Article  PubMed  Google Scholar 

  • Ryu I S, Kim J S, Roh J L, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas. J Nucl Med, 2013; 54(7):1032-1038.

    Article  CAS  PubMed  Google Scholar 

  • Sharma P, Jain T K, Singh H, et al. Utility of 18F-FDG PET/CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience. Nucl Med Commun, 2013; 34 (3):211-219.

    Article  CAS  PubMed  Google Scholar 

  • Toriihara A, Nakamura S, Kubota K, et al. Can dual-time-point 18F-FDG PET/CT differentiate malignant salivary gland tumors from benign tumors?. AJR Am J Roentgenol, 2013; 201(3):639-644.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Li, L., Pang, W., Jin, S., Wang, Y. (2023). PET/CT of Salivary Gland Tumors. In: Yao, Z., Li, S. (eds) Atlas of PET/CT in Oncology - Volume 1. Springer, Singapore. https://doi.org/10.1007/978-981-99-1172-1_19

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-1172-1_19

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-1171-4

  • Online ISBN: 978-981-99-1172-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics